Evaluating the Potential and Limitations of Liquid Biopsies in Cancer Screening
Liquid biopsies offer a promising avenue for early cancer detection, but current evidence is insufficient to confirm their effectiveness and safety. Experts call for more rigorous research before widespread adoption.
Liquid biopsies, which analyze blood samples to detect circulating DNA, proteins, and other biomarkers associated with various cancers, are garnering significant interest for their potential to identify tumors that are otherwise difficult to detect early. Several laboratory-developed multi-cancer detection (MCD) tests—such as OneTest, Galleri, OncoSeek, and the newly launched Cancerguard—are available for purchase online with a doctor's note, although none have received approval from the U.S. Food and Drug Administration (FDA). These tests are priced around $950 and aim to enhance early detection, especially for cancers lacking standard screening options, which account for up to 70% of cancer-related deaths.
However, the effectiveness of these tests in real-world settings remains uncertain. A comprehensive review of 20 studies involving over 109,000 individuals revealed significant variability in test accuracy depending on the type of cancer, the study design, and the population tested. Currently, there's a lack of controlled, clinical trials demonstrating that MCD tests improve cancer detection rates, reduce mortality, or enhance quality of life. The primary concern is the potential for false positives, which can lead to unnecessary invasive procedures, anxiety, and stress for healthy individuals.
Experts emphasize that, despite the technological advancements, the scientific community needs more rigorous research to establish the clinical benefits of liquid biopsies. The current evidence does not sufficiently weigh the benefits against the harms, and insurance coverage for such tests is often unavailable.
In conclusion, while liquid biopsies hold promise for revolutionizing cancer screening, their widespread use should be approached with caution. Additional controlled studies are essential to determine their true utility and to develop guidelines for their integration into clinical practice.
source: https://medicalxpress.com/news/2025-09-liquid-biopsies-cancer-screening.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Ultrasound Method Enhances Early Diagnosis of Peripheral Artery Disease
A new ultrasound method improves early detection of peripheral artery disease, offering faster, more reliable diagnosis to prevent severe complications.
Understanding Déjà Vu: The Strange Phenomenon of the Mind
Discover the scientific explanation behind déjà vu, a common brain phenomenon that creates a fleeting sense of familiarity, and how it offers insights into memory and brain functioning.
The Potential of Human iPSC-Heart Cells in Fentanyl Opioid Research
Recent studies utilizing human iPSC-derived cardiomyocytes reveal fentanyl’s detrimental effects on heart rhythm, providing new insights into overdose-related cardiac risks and potential for personalized research approaches.
Florida Ends All Vaccine Mandates as West Coast States Establish Independent Guidelines
Florida plans to eliminate all vaccine mandates, while West Coast states establish their own immunization guidelines amid ongoing debates over public health policies and individual freedoms.